Abstract
Background
In recent times, pancreatitis has been one of the most frequently reported adverse events for sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Aim
To evaluate the potential association between SGLT2 inhibitors and the risk of pancreatitis by analyzing the spontaneous reports through disproportionality analysis and reviewing case reports.
Method
A retrospective case/non-case study was conducted using spontaneous reports from the FDA Adverse Event Reporting System (FAERS), VigiBase, and the Canadian Adverse Reaction Database (CARD). Disproportionality analysis was performed by calculating the Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and the Information Component (IC). In parallel, a review of case reports was conducted on SGLT2 inhibitors-induced pancreatitis.
Results
A total of 524, 510, and 40 spontaneous reports of pancreatitis suspected to be caused by SGLT2 inhibitors were identified from FAERS, VigiBase, and CARD, respectively. Through the disproportionality analysis of FAERS data, a signal was identified between the SGLT2 inhibitors and pancreatitis, with empagliflozin having highest risk [PRR = 3.9; Lower Bound (LB) ROR = 3.4; IC025 = 1.7], followed by canagliflozin [PRR = 3.6; LB ROR = 3.2; IC025 = 1.6], and dapagliflozin [PRR = 3.2; LB ROR = 2.7; IC025 = 1.4]. VigiBase and CARD data analyses reiterated the findings of FAERS. Thirteen case reports identified from a systematic literature search strengthened these findings and highlighted the importance of physical examination and laboratory parameters for the early diagnosis of pancreatitis.
Conclusion
The current study found a potential risk of pancreatitis with the use of SGLT2 inhibitors. There is an urgent need to thoroughly investigate the same and take the necessary action to avoid or minimize the risk.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tabish SA. Is diabetes becoming the biggest epidemic of the twenty-first century? Int J Health Sci (Qassim). 2007;1:V–VIII.
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2019;157:107843.
Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.
Bastaki A. Diabetes mellitus and its treatment. Int J Diabetes Metab. 2005;13:111–34.
Ferrannini E, Solini A. SGLT-2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495–502.
Scheen AJ. An update on the safety of SGLT-2 inhibitors. Expert Opin Drug Saf. 2019;18:295–311.
Janssen Labels. Highlights of prescribing information for INVOKANA. 2020. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf. Accessed 20 Jul 2022
Kluger AY, Tecson KM, Barbin CM, et al. Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review. Rev Cardiovasc Med. 2018;19:41–9.
Rastogi A, Bhansali A. SGLT-2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review. Diabetes Ther. 2017;8:1245–51.
Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796–803.
Böhm R, von Hehn L, Herdegen T, et al. OpenVigil FDA–inspection of US American adverse drug events pharmacovigilance data and novel clinical applications. PLoS ONE. 2016;11:e0157753.
Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23:60–3.
Badwal K, Tariq T, Peirce D. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient presenting with acute pancreatitis. Case Rep Endocrinol. 2018;2018:6450563.
Chowdhary M, Kabbani AA, Chhabra A. Canagliflozin-induced pancreatitis: a rare side effect of a new drug. Ther Clin Risk Manag. 2015;11:991–4.
Dziadkowiec KN, Stawinski PM, Proenza J. Empagliflozin-associated pancreatitis: a consideration for SGLT-2 Inhibitors. ACG Case Rep J. 2021;8(1):e00530.
Gutch M, Bhattacharya A, Kumar S, et al. Dapagliflozin induced pancreatitis. Int J Med Public Health. 2018;8:45–7.
Lightbourne T, Najafian N, McCarty TR. Consideration for empagliflozin-associated pancreatitis. Am J Gastroenterol. 2017;112:S710.
McIntire DR, Bayne DB. Empagliflozin-induced pancreatitis. Ann Pharmacother. 2018;52:1158–9.
Oliveira M, Narayanan A, Yamanaka T, et al. Empagliflozin is a pain in my pancreas: A rare case of drug induced pancreatitis in the setting of DKA. 2020. https://shmabstracts.org/abstract/empagliflozin-is-a-pain-in-my-pancreas-a-rare-case-of-drug-induced-pancreatitis-in-the-setting-of-dka/. Accessed 20 Jul 2022
Patel KM, Pikas E, George T. Drug-induced necrotizing pancreatitis with a focus on canagliflozin. Am J Ther. 2017;24:e496.
Saunders E, Lowe R. Acute pancreatitis as a rare side effect of empagliflozin. Boston Medical Center. 2020. https://www.bumc.bu.edu/im-residency/acute-pancreatitis-as-a-rare-side-effect-of-empagliflozin/. Accessed 20 Jul 2022
Srivali N, Thongprayoon C, Cheungpasitporn W, et al. Acute pancreatitis in the use of canagliflozin: a rare side effect of the novel therapy for type 2 diabetes mellitus. J Basic Clin Pharma. 2015;6:101–2.
Sujanani SM, Elfishawi MM, Zarghamravanbaksh P, et al. Dapagliflozin-induced acute pancreatitis: a case report and review of literature. Case Rep Endocrinol. 2020;2020:6724504.
Verma R. Canagliflozin-associated acute pancreatitis. Am J Ther. 2016;23:e972–3.
Zeidan BS Jr, Boadu C, Hernandez A, et al. Adverse side effects: empagliflozin-related acute pancreatitis case report. Cureus. 2020;12:e12325.
Frent I, Bucsa C, Leucuta D, et al. An investigation on the association between sodium glucose co-transporter 2 inhibitors use and acute pancreatitis: a VigiBase study. Pharmacoepidemiol Drug Saf. 2021. https://doi.org/10.1002/pds.5313.
Tang H, Yang K, Li X, et al. Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2020;29:161–72.
Suga T, Kikuchi O, Kobayashi M, et al. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT-2 inhibitors on plasma glucagon levels. Mol Metab. 2019;19:1–12.
Acknowledgements
The authors thank the providers of the FDA Adverse Event Reporting System (FAERS), VigiBase, Canadian Adverse Event Reporting Database (CAERD), and OpenVigil 2.1. Thanks to the authorities of the National Institute of Pharmaceutical Education and Research (NIPER) Guwahati and the National Coordination Centre-Pharmacovigilance Programme of India (PvPI) for their constant support while conducting this study.
Funding
The authors have not disclosed any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Palapra, H., Viswam, S.K., Kalaiselvan, V. et al. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports. Int J Clin Pharm 44, 1425–1433 (2022). https://doi.org/10.1007/s11096-022-01476-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-022-01476-7